Oryx 1 gm/vial (IM Injection)
Medicine Details
Category | Details |
---|---|
Generic | Ceftriaxone sodium |
Company | Rangs pharmaceuticals ltd |
Also available as |
Indications
- Lower respiratory tract infections
- Acute Bacterial Otitis Media
- Skin and skin structure infections
- Urinary tract infections
- Gonorrhea
- Bacterial Septicemia
- Bone and joint infections
- Meningitis
- Prevention of postoperative infections
- Perioperative prophylaxis of infections associated with surgery
Pharmacology
Ceftriaxone is a 3rd generation broad-spectrum parenteral cephalosporin antibiotic with potent bactericidal activity against a wide range of Gram-positive and Gram-negative organisms. It kills bacteria by interfering with the synthesis of the bacterial cell wall. Ceftriaxone has a long plasma elimination half-life of about 6 to 9 hours, which allows for once-daily dosage. It is not metabolized in the body and is highly protein bound (95%).
Dosage
- Adult:
- 1 to 2 gm by intravenous or intramuscular administration once a day
- 1 to 2 g IV or IM once a day (or in equally divided doses twice a day) for various infections
- Max dose: 4 gm/day
- Infants and Children (01 month or older):
- 50 to 75 mg/kg intravenously or intramuscularly once a day
- Duration: 4 to 14 days; longer in complicated infections
Administration
- Preparation of Solutions for Intramuscular / Intravenous Injections
- For Intramuscular Injection: 250 mg or 500 mg Ceftriaxone should be dissolved in Lidocaine HCI 1% injection
- For Intravenous Injection: 250 mg or 500 mg Ceftriaxone should be dissolved in Water for injection
Interaction
No drug interactions reported
Contraindications
Not to be given to patients with a history of hypersensitivity to cephalosporin antibiotics
Side Effects
- Gastro-intestinal effects including diarrhea, nausea, and vomiting
- Cutaneous reactions including rash, urticaria, and edema
- Hematologic reactions including eosinophilia and thrombocytopenia
- Hepatic reactions including elevations of SGOT or SGPT
- CNS reactions including nervousness, confusion, and headache
- Local phlebitis occurs rarely following intravenous administration
Pregnancy & Lactation
Safety in human pregnancy not established; caution in lactating mother
Precautions & Warnings
- Anaphylactic shock may occur
- Gallbladder sludge detected in rare cases
- Regular blood picture checks during prolonged treatment
Use in Special Populations
Must not be given to premature and newborn neonates (up to 28 days of age)
Overdose Effects
No specific antidote; treatment should be symptomatic
Therapeutic Class
Third generation Cephalosporins
Storage Conditions
Store vial in a cool, dry place (below 30° C), away from light & moisture; Keep out of the reach of children
Related Brands
- Oryx 250 mg/vial (IV Injection) - rangs-pharmaceuticals-ltd
- Oryx 500 mg/vial (IV Injection) - rangs-pharmaceuticals-ltd
- Oryx 1 gm/vial (IV Injection) - rangs-pharmaceuticals-ltd
- Parcef 250 mg/vial (IM Injection) - jayson-pharmaceuticals-ltd
- Parcef 500 mg/vial (IM Injection) - jayson-pharmaceuticals-ltd